SMC April Update
The Scottish Medicines Consortium has issued its monthly advice on new medicines.
Vildagliptin (Galvus®) has been accepted for restricted use in combination with metformin in patients who are inappropriate for sulphonylureas and have insufficient glycaemic control despite maximal tolerated dose of metformin. This submission did not examine combination use of vildagliptin with sulphonylureas or glitazones.
Insulin glulisine (Apidra®) and insulin glargine (Lantus®) in pre-filled pens (Solostar®) have been accepted for use in patients who require insulin where insulin analogues are appropriate and a pre-filled device offers advantages over a pen and cartridge device. Both of these advisory documents also clarify where the use of insulin analogues is appropriate in relation to established insulin products.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.
| « Drug Safety Update, Issue 9 | Sativex results disappointing » |
Leave a Comment